Here are the Form 4 insider transactions from Estrella Immunopharma, Inc. (ESLA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ESLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLA filings page.
Estrella Immunopharma, Inc. CEO Cynthia Pussinen was granted options covering 1,000,000 common shares, with an exercise price of $0.43 per share. The options vest as to 25% on October 25, 2027, and the remaining 75% in 36 substantially equal monthly installments thereafter, subject to continued service through each vesting date. They expire November 2, 2036 and were granted under the 2023 Omnibus Incentive Plan, with advance approval by the Compensation Committee and Board of Directors in accordance with Rule 16b-3(d).
Estrella Immunopharma, Inc. (ESLA) reported that CEO and director Liu Cheng exercised stock options for 100,000 shares of common stock on 2026-08-25 at an exercise price of $0.815 per share. Following the exercise, Cheng directly holds 397,437 shares of common stock and 900,000 incentive stock options related to this award remain outstanding.
The options were granted on 2024-10-30 under the 2023 Omnibus Incentive Plan, with 25% immediately exercisable at grant and the remainder vesting in equal monthly installments of 1/48th of the total award; the options exercised were vested.
Estrella Immunopharma, Inc. (ESLA) reported that its Chief Financial Officer, Jiandong Xu, exercised 100,000 Incentive Share Options on 2026-08-18 at an exercise price of $0.815 per share, receiving an equal number of common shares. Following the exercise, Xu directly holds 365,488 shares of common stock and 390,796 incentive share options. The options exercised were granted on 2024-10-30 under the 2023 Omnibus Incentive Plan and were vested as to the shares exercised.
Estrella Immunopharma’s Chief Financial Officer, Jiandong Xu, reported a series of open-market purchases of the company’s common stock. On October 7, 2025, he bought 1,000 shares at $1.33 per share, bringing his direct holdings to 265,488 shares.
Earlier, on September 11, 2025, Xu purchased 100 shares at $1.04 per share. On September 22, 2025, 1,000 shares were purchased at $1.16 per share and are held by his spouse, totaling 16,700 shares in that account. The filing states Xu disclaims beneficial ownership of the spouse-held shares for Section 16 and other purposes.